Alpine Immune Sciences, Inc. (ALPN): Price and Financial Metrics

Alpine Immune Sciences, Inc. (ALPN): $16.02

0.39 (+2.50%)

POWR Rating

Component Grades








Add ALPN to Watchlist
Sign Up

Industry: Biotech




#82 of 345

in industry

ALPN Price/Volume Stats

Current price $16.02 52-week high $16.33
Prev. close $15.63 52-week low $5.81
Day low $15.19 Volume 748,004
Day high $16.33 Avg. volume 280,550
50-day MA $12.03 Dividend yield N/A
200-day MA $10.58 Market Cap 930.73M

ALPN Stock Price Chart Interactive Chart >


  • ALPN scores best on the Sentiment dimension, with a Sentiment rank ahead of 86.33% of US stocks.
  • ALPN's strongest trending metric is Growth; it's been moving up over the last 177 days.
  • ALPN ranks lowest in Stability; there it ranks in the 17th percentile.

ALPN Stock Summary

  • Of note is the ratio of ALPINE IMMUNE SCIENCES INC's sales and general administrative expense to its total operating expenses; just 7.7% of US stocks have a lower such ratio.
  • With a price/sales ratio of 20.64, ALPINE IMMUNE SCIENCES INC has a higher such ratio than 94.9% of stocks in our set.
  • With a year-over-year growth in debt of -38.7%, ALPINE IMMUNE SCIENCES INC's debt growth rate surpasses only 8.11% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to ALPINE IMMUNE SCIENCES INC, a group of peers worth examining would be CARA, ABUS, ALT, IDYA, and VIR.
  • ALPN's SEC filings can be seen here. And to visit ALPINE IMMUNE SCIENCES INC's official web site, go to

ALPN Valuation Summary

  • ALPN's price/earnings ratio is -13.5; this is 155.56% lower than that of the median Healthcare stock.
  • Over the past 102 months, ALPN's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for ALPN.

Stock Date P/S P/B P/E EV/EBIT
ALPN 2023-11-03 27.2 4.7 -13.5 -13.3
ALPN 2023-11-02 24.9 4.3 -12.4 -12.1
ALPN 2023-11-01 17.8 3.1 -8.8 -8.6
ALPN 2023-10-31 17.3 3.0 -8.6 -8.3
ALPN 2023-10-30 16.5 2.8 -8.2 -7.9
ALPN 2023-10-27 15.7 2.7 -7.8 -7.5

ALPN Growth Metrics

    The year over year net income to common stockholders growth rate now stands at -42.87%.
  • Its 2 year price growth rate is now at 120%.
  • Its 5 year net income to common stockholders growth rate is now at -7.57%.
Over the past 33 months, ALPN's revenue has gone up $30,078,000.

The table below shows ALPN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 31.818 -41.697 -54.065
2022-06-30 31.967 4.785 -54.286
2022-03-31 33.868 6.172 -47.217
2021-12-31 23.443 -15.248 -50.333
2021-09-30 24.556 -9.868 -41.508
2021-06-30 17.953 -45.394 -34.151

ALPN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ALPN has a Quality Grade of C, ranking ahead of 68.11% of graded US stocks.
  • ALPN's asset turnover comes in at 0.122 -- ranking 247th of 682 Pharmaceutical Products stocks.
  • SELB, TXMD, and QGEN are the stocks whose asset turnover ratios are most correlated with ALPN.

The table below shows ALPN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.122 1 -0.458
2021-03-31 0.086 1 -0.661
2020-12-31 0.083 1 -0.777
2020-09-30 0.051 1 -1.140
2020-06-30 0.044 1 -0.895
2020-03-31 0.047 1 -0.716

ALPN Price Target

For more insight on analysts targets of ALPN, see our ALPN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $20.00 Average Broker Recommendation 1.25 (Strong Buy)

Alpine Immune Sciences, Inc. (ALPN) Company Bio

Alpine Immune Sciences, Inc. is focused on developing novel protein‐based immunotherapies using its proprietary Variant Ig Domain vIgD platform technology. The vIgD platform is designed to interact with multiple targets, including many present in the immune synapse. Alpine’s vIgDs are developed using a process known as directed evolution, which can potentially produce proteins capable of either enhancing or diminishing an immune response and thereby may potentially apply therapeutically to both oncology and inflammatory diseases. The company formed following a July, 2017 merger with Nivalis Therapeutics.

ALPN Latest News Stream

Event/Time News Detail
Loading, please wait...

ALPN Latest Social Stream

Loading social stream, please wait...

View Full ALPN Social Stream

Latest ALPN News From Around the Web

Below are the latest news stories about ALPINE IMMUNE SCIENCES INC that investors may wish to consider to help them evaluate ALPN as an investment opportunity.

Alpine Immune Sciences Presents New Translational Data on Povetacicept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023

SEATTLE, November 15, 2023--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced today that the Company presented new translational data for povetacicept (ALPN-303) in systemic lupus erythematosus (SLE) at the American College of Rheumatology Convergence 2023, November 10-15, 2023.

Yahoo | November 15, 2023

Alpine Immune Sciences Inc (ALPN) Reports Encouraging Q3 2023 Results; Advances Povetacicept ...

Equity Offering and Clinical Data Set Stage for Pivotal 2024 Trials

Yahoo | November 15, 2023

Alpine Immune Sciences Reports Third Quarter 2023 Financial Results

SEATTLE, November 14, 2023--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results and company highlights for the third quarter ended September 30, 2023.

Yahoo | November 14, 2023

Orbimed Advisors LLC Bolsters Portfolio with Alpine Immune Sciences Inc Stake

Orbimed Advisors LLC, a prominent investment firm, has recently expanded its portfolio by adding shares of Alpine Immune Sciences Inc (NASDAQ:ALPN). On November 9, 2023, the firm acquired 145,251 additional shares of the biopharmaceutical company, bringing its total holdings to 4,226,843 shares. This transaction reflects a 0.03% impact on Orbimed's portfolio, with the shares purchased at an average price of $12.06.

Yahoo | November 14, 2023

Is Alcon (ALC) Stock Outpacing Its Medical Peers This Year?

Here is how Alcon (ALC) and Alpine Immune Sciences, Inc. (ALPN) have performed compared to their sector so far this year.

Yahoo | November 13, 2023

Read More 'ALPN' Stories Here

ALPN Price Returns

1-mo -0.31%
3-mo 25.94%
6-mo 51.56%
1-year 146.46%
3-year 62.31%
5-year N/A
YTD 117.96%
2022 -46.93%
2021 9.92%
2020 228.13%
2019 4.35%
2018 -67.14%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!